Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H36N2O4 |
Molecular Weight | 452.5857 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=C(C=CC(CC(=O)N[C@H](CC(C)C)C2=C(C=CC=C2)N3CCCCC3)=C1)C(O)=O
InChI
InChIKey=FAEKWTJYAYMJKF-HSZRJFAPSA-N
InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m1/s1
R-enantiomer, AG-EE 624 ZW, is more than 100 fold less active than S-enantiomer as hypoglycaemic compound. It is critical to test and control the content of R(–) isomer in repaglinide to assure the quality of tablet. Repaglinide is an oral medication used for blood sugar control in type 2 diabetes mellitus.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Highly potent and stereoselective effects of the benzoic acid derivative AZ-DF 265 on pancreatic beta-cells. | 1988 Jan |
|
Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets. | 1989 Apr 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9283692
Rat, Oral: 0.1, 0.3 and 1.0 mg/kg
Rat, Intravenous: 0.1, 1 mg/kg
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10479034
Created by
admin on Sat Dec 16 09:26:03 GMT 2023 , Edited by admin on Sat Dec 16 09:26:03 GMT 2023
|
PRIMARY | |||
|
85M30X62FM
Created by
admin on Sat Dec 16 09:26:03 GMT 2023 , Edited by admin on Sat Dec 16 09:26:03 GMT 2023
|
PRIMARY | |||
|
1600868
Created by
admin on Sat Dec 16 09:26:03 GMT 2023 , Edited by admin on Sat Dec 16 09:26:03 GMT 2023
|
PRIMARY | |||
|
147852-26-4
Created by
admin on Sat Dec 16 09:26:03 GMT 2023 , Edited by admin on Sat Dec 16 09:26:03 GMT 2023
|
PRIMARY | |||
|
DTXSID70163818
Created by
admin on Sat Dec 16 09:26:03 GMT 2023 , Edited by admin on Sat Dec 16 09:26:03 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD